Hims & Hers Health (NYSE:HIMS) COO Michael Chi Sells 97,289 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Hims & Hers Health Trading Down 7.0%

NYSE:HIMS opened at $23.23 on Thursday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The firm has a 50 day moving average of $23.19 and a 200 day moving average of $36.98. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of 45.55, a PEG ratio of 2.80 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.11 earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health in the second quarter valued at about $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new stake in Hims & Hers Health in the third quarter valued at approximately $28,000. Finally, Bogart Wealth LLC increased its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Partnership with Novo Nordisk opens a pre‑launch waitlist for Ozempic and Wegovy, giving HIMS direct access to high‑demand branded GLP‑1s via its telehealth platform — a clear revenue growth opportunity and a resolution of prior disputes with Novo. Novo Nordisk Partners With Hims & Hers — Yahoo Finance
• Positive Sentiment: Sell‑side optimism: at least one research note cited in the press forecasts meaningful upside for HIMS, which could support longer‑term investor sentiment if execution on GLP‑1 access drives subscription and prescription volume. Leerink Forecasts Strong Price Appreciation — AmericanBankingNews
• Neutral Sentiment: Industry pieces and investor commentary are highlighting HIMS among telehealth/weight‑loss winners; these are background for interest but don’t by themselves change fundamentals. Seeking Alpha: Value Investing With Raul Shah
• Negative Sentiment: Insider selling: multiple insiders (including COO Michael Chi) disclosed sizable stock sales on March 17th — large insider dispositions can signal near‑term owner liquidity or reduced conviction and often weigh on sentiment. SEC Form 4 — Michael Chi SEC Form 4 — Soleil Boughton
• Negative Sentiment: Pricing risk for GLP‑1s: analysts note pricing competition between major players (Novo Nordisk vs. Eli Lilly) will increasingly be a factor — lower prices or faster discounting could pressure gross margins and ARPU from new GLP‑1 prescriptions. Health Care Roundup — Yahoo Finance
• Negative Sentiment: Near‑term price reaction: trade commentary and market reports show HIMS underperformed the broader market in the latest session, indicating short‑term selling pressure even as strategic positives remain. Zacks — HIMS Suffers Larger Drop

Wall Street Analyst Weigh In

Several research analysts recently issued reports on HIMS shares. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and upped their target price for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. TD Cowen dropped their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research note on Tuesday, February 24th. Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Barclays increased their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Finally, Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Monday, March 9th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $31.29.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.